Category Archives: Yunnan

Policy Analysis and Guidance: Yunnan Announces Second Supply Enterprises for National Drug Procurement

Leave a reply

Yunnan Province’s Government Procurement and Tendering Center has issued an announcement regarding the declaration of second supply enterprises for the tenth batch of national centralized drug procurement. This initiative aims to ensure the stability of drug supply, address market gaps, and enhance the efficiency of the centralized procurement system.

Key Policy Highlights

  1. Drug Scope and Qualification
    • Drugs Included: The announcement covers 10 specific drug varieties, including esmolol injection, aminocaproic acid injection, and others.
    • Eligibility: Enterprises that are not primary or first backup suppliers for these drugs in Yunnan can apply.
  2. Price Declaration and Backup Enterprise Determination
    • Price Limits: Enterprises must declare prices no higher than 1.5 times their winning price or the highest winning price for the same variety.
    • Selection Criteria: The lowest bidder is selected as the backup enterprise; if prices are equal, enterprises producing their own raw materials have priority.
  3. Submission and Bidding Details
    • Submission Deadline: Materials must be submitted by 10:00 AM on April 2, 2025.
    • Location: Kunming High-Tech Zone, Building 1, Transaction Building, No. 269 Kefa Road.
    • Requirements: Materials must be sealed and accompanied by authorization documents.
  4. Bidding and Opening Details
    • Bidding Time: Same as submission deadline.
    • Location: Same as submission location.

Policy Orientation and Industry Implications
The announcement reflects Yunnan’s strategic focus on:

  • Supply Chain Resilience: Ensuring continuous drug availability through diversified supply sources.
  • Market Adaptability: Adapting procurement strategies to meet evolving market conditions.
  • Transparency: Enhancing clarity and accessibility of procurement information for stakeholders.

Conclusion
Yunnan’s approach to determining second supply enterprises underscores its commitment to maintaining a stable and responsive pharmaceutical market. This policy supports the reliability of the centralized procurement system and ensures patient access to essential medications. Stakeholders should stay informed of these updates to maintain operational efficiency and compliance.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25181&CatalogId=3